Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898
Table 3 Timing and frequency of Happi ER prescribed, antacid consumption, and other ongoing treatments
| Variables | Frequency | Percentage |
| Timing of Happi ER prescribed | ||
| Before breakfast | 912 | 89.24 |
| Before lunch | 04 | 0.39 |
| Before dinner | 286 | 27.98 |
| Frequency of Happi ER | ||
| Once daily | 864 | 84.54 |
| Twice daily | 158 | 15.46 |
| Antacid consumption in previous week | ||
| Yes | 190 | 18.59 |
| No | 832 | 81.41 |
| Other ongoing treatments | ||
| Yes | 320 | 31.31 |
| No | 702 | 68.69 |
- Citation: Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898
- URL: https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i1.103898